» Articles » PMID: 31240161

A Novel Missense Variant in Causes Recessive Brain Monoamine Vesicular Transport Disease and Absent Serotonin in Platelets

Overview
Journal JIMD Rep
Publisher Wiley
Date 2019 Jun 27
PMID 31240161
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Brain monoamine vesicular transport disease is an infantile onset neurodevelopmental disorder caused by variants in , which codes for the vesicular monoamine transporter 2 (VMAT2) protein, involved in the transport of monoamines into synaptic vesicles and of serotonin into platelet dense granules.

Case Presentation: The presented case is of a child, born of healthy consanguineous parents, who exhibited hypotonia, mental disability, epilepsy, uncontrolled movements, and gastrointestinal problems. A trial treatment with L-DOPA proved unsuccessful and the exact neurological involvement could not be discerned due to normal metabolic and brain magnetic resonance imaging results.Platelet studies and whole genome sequencing were performed. At age 4, the child's platelets showed a mild aggregation and adenosine triphosphate secretion defect that could be explained by dysmorphic dense granules observed by electron microscopy. Interestingly, the dense granules were almost completely depleted of serotonin. A novel homozygous p.P316A missense variant in VMAT2 was detected in the patient and the consanguineous parents were found to be heterozygous for this variant. Although the presence of VMAT2 on platelet dense granules has been demonstrated before, this is the first report of defective platelet dense granule function related to absent serotonin storage in a patient with VMAT2 deficiency but without obvious clinical bleeding problems.

Conclusions: This study illustrates the homology between serotonin metabolism in brain and platelets, suggesting that these blood cells can be model cells for some pathways relevant for neurological diseases. The literature on VMAT2 deficiency is reviewed.

Citing Articles

Tricyclic and tetracyclic antidepressants upregulate VMAT2 activity and rescue disease-causing VMAT2 variants.

Wang X, Marmouzi I, Finnie P, Bucher M, Yan Y, Williams E Neuropsychopharmacology. 2024; 49(11):1783-1791.

PMID: 39060436 PMC: 11399425. DOI: 10.1038/s41386-024-01914-2.


Neurotoxicology of dopamine: Victim or assailant?.

Bucher M, Dicent J, Hospital C, Miller G Neurotoxicology. 2024; 103:175-188.

PMID: 38857676 PMC: 11694735. DOI: 10.1016/j.neuro.2024.06.001.


Dopamine synthesis and transport: current and novel therapeutics for parkinsonisms.

Tai M, Gamiz-Arco G, Martinez A Biochem Soc Trans. 2024; 52(3):1275-1291.

PMID: 38813865 PMC: 11346439. DOI: 10.1042/BST20231061.


Novel SLC18A2 Variant in Infantile Dystonia-Parkinsonism Type 2.

Kaasalainen S, Arikka H, Martikainen M, Kaasinen V Case Rep Neurol Med. 2024; 2024:4767647.

PMID: 38716424 PMC: 11074866. DOI: 10.1155/2024/4767647.


Structural mechanisms for VMAT2 inhibition by tetrabenazine.

Dalton M, Cheng M, Bahar I, Coleman J Elife. 2024; 12.

PMID: 38517752 PMC: 10959523. DOI: 10.7554/eLife.91973.


References
1.
Ehrlich D, Humpel C . Platelets in psychiatric disorders. World J Psychiatry. 2013; 2(6):91-4. PMC: 3782188. DOI: 10.5498/wjp.v2.i6.91. View

2.
Ambrosio A, Di Pietro S . Storage pool diseases illuminate platelet dense granule biogenesis. Platelets. 2016; 28(2):138-146. PMC: 5994342. DOI: 10.1080/09537104.2016.1243789. View

3.
Jacobsen J, Wilson C, Cunningham V, Glamuzina E, Prosser D, Love D . Brain dopamine-serotonin vesicular transport disease presenting as a severe infantile hypotonic parkinsonian disorder. J Inherit Metab Dis. 2015; 39(2):305-8. DOI: 10.1007/s10545-015-9897-6. View

4.
Zhang Y, Chen K, Sloan S, Bennett M, Scholze A, OKeeffe S . An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci. 2014; 34(36):11929-47. PMC: 4152602. DOI: 10.1523/JNEUROSCI.1860-14.2014. View

5.
Ng J, Papandreou A, Heales S, Kurian M . Monoamine neurotransmitter disorders--clinical advances and future perspectives. Nat Rev Neurol. 2015; 11(10):567-84. DOI: 10.1038/nrneurol.2015.172. View